SAGE Therapeutics IncSAGE Therapeutics Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The dashboard includes a questions and answers table about SAGE Therapeutics Inc. This analysis of SAGE Therapeutics Inc uses data from across the web and also from public filings by SAGE Therapeutics Inc. The Sustainability rating for SAGE Therapeutics Inc represents its reporting of the United Nations Sustainable Development Goals.

SAGE Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.3; made up of an environmental score of 2.7, social score of 4.6 and governance score of 2.7.

SDG Transparency Score for SAGE Therapeutics Inc 

3.3

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2024-05-01
What drives the score for SAGE Therapeutics Inc 
2.7

Environmental

4.6

Social

2.7

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Caladrius Biosciences Inc
8.0
High
1Can Fite Biopharma Ltd
8.0
High
.........
1234Quanterix Corp
3.4
Medium
1234X4 Pharmaceuticals Inc
3.4
Medium
1253SAGE Therapeutics Inc
3.3
Medium
1253Calithera Biosciences Inc
3.3
Medium
1253Cara Therapeutics Inc
3.3
Medium
.........
1970Zyden Gentec Ltd
0.0
Low
1970iNtRON Biotechnology Inc
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does SAGE Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc report the average age of the workforce?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc offer flexible work?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc conduct supply chain audits?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does SAGE Therapeutics Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose water use targets?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did SAGE Therapeutics Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has SAGE Therapeutics Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is SAGE Therapeutics Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose its waste policy?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose energy use targets?

LockedSign up for free to unlock

Does SAGE Therapeutics Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does SAGE Therapeutics Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for SAGE Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Sorry!

Failed to process!